KURAKura Oncology, Inc.
$10.51+11% 1Y
$10.51
$7.4052 weeks$13.59
KURA in its own filings
Nothing in KURA's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
259
Events found in the filings · across 805 filings · the record starts in 2008
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 9, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 4, 2008
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Change in certifying accountanthistorical
- 2015-03-12
- SEC comment-letter activity22 occurrences
- 2024-02-29
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026Effective as of September 8, 2026, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointed Jennifer Fulk as the Company’s Chief Financial Officer, principal financial officer (replacing Troy E. Wilson, Ph.D., J.D. solely with respect to such role) and principal accounting officer …Director or officer change · Form 8-K
- Aug 12, 2026Kura Oncology Reports SECOND Quarter 2026 Financial Results.Earnings release · press release
- Jul 29, 2026On July 24, 2026, Kura Oncology, Inc. (the “Company”) entered into a Second Amended and Restated Executive Employment Agreement with Troy E. Wilson, Ph.D., J.D., the Company’s Chairman, President and Chief Executive Officer (the “Wilson Agreement”) to, among other things, modify certain severance provisions.Director or officer change · Form 8-K
- Jun 4, 2026On April 9, 2026, our Board of Directors (the “Board”), upon the recommendation of the Compensation Committee of the Board, amended the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”) and the 2015 Employee Stock Purchase Plan (the “ESPP”), in each case subject to stockholder …Director or officer change · Form 8-K
- May 12, 2026Kura Oncology Reports FIRST Quarter 2026 Financial Results.Earnings release · press release
- Mar 5, 2026Kura Oncology Reports Fourth Quarter and full year 2025 Financial Results.Earnings release · press release
- Jan 29, 2026On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.Charter/bylaw amendment or fiscal-year change · Form 8-K
- Jan 12, 2026Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones.Earnings release · press release
- Dec 2, 2025On December 2, 2025, Kura Oncology, Inc. (the “Company”) announced the first U.S. commercial sale of KOMZIFTI ™ (ziftomenib) has been completed.Other event · Form 8-K
- Nov 13, 2025On November 13, 2025, Kura Oncology, Inc. (the “Company”) and Kyowa Kirin Co., Ltd. (“Kyowa Kirin”) announced that the U.S. Food and Drug Administration (“FDA”) has granted full approval of KOMZIFTI TM (ziftomenib) for adult patients with relapsed or refractory (“R/R”) acute myeloid leukemia (“AML”) with a susceptible …Other event · Form 8-K
- Nov 4, 2025Kura Oncology Reports Third Quarter 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…